about
The First 50 Years of Molecular PharmacologyWhen and how do seizures kill neurons, and is cell death relevant to epileptogenesis?Cyclooxygenase-2 in epilepsy.Glutamate receptor ion channels: structure, regulation, and functionQuantitative transcriptional neuroanatomy of the rat hippocampus: evidence for wide-ranging, pathway-specific heterogeneity among three principal cell layersCancer and virus leads by HTS, chemical design and SEA data miningLead optimization studies of cinnamic amide EP2 antagonistsBlocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication.Development of second generation EP2 antagonists with high selectivityAstrocytes in the epileptic brain.The prostaglandin EP1 receptor potentiates kainate receptor activation via a protein kinase C pathway and exacerbates status epilepticusSubunit-dependent modulation of kainate receptors by muscarinic acetylcholine receptorsSmall molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticusTherapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticusCandidate drug targets for prevention or modification of epilepsyEP2 Receptor Signaling Regulates Microglia Death.Reduction in delayed mortality and subtle improvement in retrograde memory performance in pilocarpine-treated mice with conditional neuronal deletion of cyclooxygenase-2 geneTranscriptional profile of hippocampal dentate granule cells in four rat epilepsy modelsEpigenetics and epilepsy.Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.EP2 receptor signaling pathways regulate classical activation of microglia.2014 Epilepsy Benchmarks: Progress and Opportunities.2014 Epilepsy Benchmarks Area I: Understanding the Causes of the Epilepsies and Epilepsy-Related Neurologic, Psychiatric, and Somatic Conditions2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression.2014 Epilepsy Benchmarks Area III: Improve Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects2014 Epilepsy Benchmarks Area IV: Limit or Prevent Adverse Consequence of Seizures and Their Treatment Across The LifespanDiscovery and characterization of carbamothioylacrylamides as EP2 selective antagonists.A New Approach for Epilepsy.Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticusControl of glutamate receptor 2 (GluR2) translational initiation by its alternative 3' untranslated regions.Ionotropic glutamate receptors: regulation by G-protein-coupled receptors.Neuroinflammatory targets and treatments for epilepsy validated in experimental models.Direct detection of a single evoked action potential with MRS in Lumbricus terrestris.Subunit-dependent modulation of kainate receptors by extracellular protons and polyamines.Inhibition by bradykinin of voltage-activated barium current in a rat dorsal root ganglion cell line: role of protein kinase C.Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.Possible mechanisms of enkephalin action on hippocampal CA1 pyramidal neurons.Inhibition of the prostaglandin E2 receptor EP2 prevents status epilepticus-induced deficits in the novel object recognition task in rats.
P50
Q26823306-7A5A01DF-543A-492B-A352-D15893064FA3Q26824190-707BCE93-EB6B-4CA5-A297-18A6F083EF77Q26827095-4E20BC34-008A-48E5-A4FE-D277F51A78BDQ28290774-FEC2DF17-5C35-4E1C-9A31-D82B1AF0A184Q30848186-81708591-3B02-41E4-BCBC-AEEAB10ED862Q33508912-954464E6-D06A-4D11-9A34-0EC0375E4153Q33654575-9C2A352C-BAA6-4F31-AC39-D95EE77AD43BQ33878208-15A3BC18-4D0A-44EB-85D9-9460107B84CCQ33939410-2AB21C7D-4D1E-48E9-90DE-28938751DF53Q34014710-3ED9EED3-15B6-46D2-B775-55F8E958F83BQ34036388-09F535BF-5AAF-4514-9E42-FED6CD80E581Q34079620-43275170-A0E7-462E-9BAF-0F050F82E3D5Q34155940-6058CD93-3593-4443-BE1C-1512D18E980FQ35287263-BDDF8574-B7EC-44EE-8903-A27EA6F7076AQ35534894-33469630-8831-4FCC-99FC-E2BD25AE2C9EQ35594944-3B4AF0E3-E4A5-483E-8B23-50E558605CD2Q35745955-55C1BCFC-B196-4844-91E9-F09A564B1FA6Q36161909-5FAFB86B-AC0A-43E8-9288-5772A7441C34Q36366722-3BFDACB8-7912-4789-889C-71D201042528Q36493159-4E129473-E531-40F3-A474-DCAA4DEA93D4Q36573214-7EB2B2F7-6754-4913-BABE-77C254344354Q36620651-0AEFA4D4-268C-41BF-9843-79ABEE8BCA38Q36725062-285A0AB6-B64D-4A45-AA16-5DD2E9F4DB18Q37021049-4CBFA605-3CD4-4165-9573-0A3802C11E8AQ37021052-9AFE2691-E525-4E41-A219-86A60C73CED8Q37021058-F484BFB7-E50F-465E-93C8-2380E3A225F8Q37021062-97F6BA4B-5CC2-4050-A2BF-B2AF9ED27F61Q37021068-31A07217-44C4-458A-B34B-E175A6152FCCQ37063800-F20B85E3-44CD-4292-ABF7-4952AE0D6AB7Q37078867-B720CA4E-A5C1-43C9-86FA-58B4ADD78BA3Q37281455-5FB58DEB-DA75-40BE-9B6E-F2F50F34F425Q37444473-ADD20414-7968-42F4-8D4F-08BA2479FCC1Q38076636-5383F8A4-0086-417D-A7B7-B37161BDACD6Q38662997-AB264A26-C04A-47D9-8DDF-C252BFCC4846Q38771607-7FD2D02E-C8B2-4A2C-AE9B-29A54BCC6224Q40668981-AB9316CA-48DA-49D4-AEFE-770C75E79E19Q41181130-42E03EEA-D76E-49D3-94B4-15E4EE390A48Q42153942-2BE05776-6F31-488D-8D26-0692843240EEQ42467317-5E2BF5E7-06B2-46E5-82DE-0F07194623E6Q42581871-A298821E-D405-4A3E-98F2-3401A4793B2D
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Raymond Dingledine
@en
Raymond Dingledine
@nl
type
label
Raymond Dingledine
@en
Raymond Dingledine
@nl
prefLabel
Raymond Dingledine
@en
Raymond Dingledine
@nl
P31
P496
0000-0001-7128-4520